$4.93 Billion is the total value of Artal Group S.A.'s 146 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 105.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARGX | Buy | ARGENX SEsponsored adr | $150,535,000 | +21.5% | 500,000 | +11.1% | 3.06% | +39.5% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $137,301,000 | +10.6% | 850,000 | +17.2% | 2.79% | +27.0% |
| FATE | Buy | FATE THERAPEUTICS INC | $117,167,000 | +9.3% | 1,350,000 | +3.8% | 2.38% | +25.6% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $56,810,000 | +16.8% | 1,000,000 | +53.8% | 1.15% | +34.1% |
| SWTX | Buy | SPRINGWORKS THERAPEUTICS INC | $41,205,000 | +40.0% | 500,000 | +25.0% | 0.84% | +60.8% |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $38,832,000 | – | 400,000 | +100.0% | 0.79% | – |
| OTLY | New | OATLY GROUP ABsponsored ads | $36,690,000 | – | 1,500,000 | +100.0% | 0.74% | – |
| REPL | Buy | REPLIMUNE GROUP INC | $34,578,000 | +41.7% | 900,000 | +12.5% | 0.70% | +62.9% |
| TALS | New | TALARIS THERAPEUTICS INC | $30,324,000 | – | 2,064,262 | +100.0% | 0.62% | – |
| VERV | New | VERVE THERAPEUTICS INC | $30,125,000 | – | 500,000 | +100.0% | 0.61% | – |
| TPTX | Buy | TURNING POINT THERAPEUTICS I | $27,307,000 | -7.7% | 350,000 | +11.9% | 0.55% | +5.9% |
| PRAX | Buy | PRAXIS PRECISION MEDICINES I | $21,936,000 | -10.7% | 1,200,000 | +60.0% | 0.44% | +2.5% |
| GRPH | New | GRAPHITE BIO INC | $21,511,000 | – | 700,000 | +100.0% | 0.44% | – |
| Buy | MARINUS PHARMACEUTICALS INC | $17,940,000 | +44.9% | 1,000,000 | +25.0% | 0.36% | +66.2% | |
| BBIO | Buy | BRIDGEBIO PHARMA INC | $16,764,000 | +8.9% | 275,000 | +10.0% | 0.34% | +25.0% |
| AMAM | New | AMBRX BIOPHARMA INCsponsored ads | $16,660,000 | – | 850,000 | +100.0% | 0.34% | – |
| DLO | New | DLOCAL LTD | $15,496,000 | – | 295,000 | +100.0% | 0.32% | – |
| LFST | New | LIFESTANCE HEALTH GROUP INC | $13,930,000 | – | 500,000 | +100.0% | 0.28% | – |
| ADAG | Buy | ADAGENE INCads | $13,560,000 | -5.6% | 1,000,000 | +25.0% | 0.28% | +8.3% |
| AGL | New | AGILON HEALTH INC | $12,171,000 | – | 300,000 | +100.0% | 0.25% | – |
| LYEL | New | LYELL IMMUNOPHARMA INC | $11,368,000 | – | 700,000 | +100.0% | 0.23% | – |
| CYCN | Buy | CYCLERION THERAPEUTICS INC | $10,838,000 | +113.7% | 2,779,122 | +52.9% | 0.22% | +144.4% |
| ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $10,500,000 | -55.6% | 3,000,000 | +25.0% | 0.21% | -49.0% |
| CYTK | New | CYTOKINETICS INC | $9,895,000 | – | 500,000 | +100.0% | 0.20% | – |
| SYRS | Buy | SYROS PHARMACEUTICALS INC | $9,265,000 | +20.8% | 1,700,000 | +65.9% | 0.19% | +39.3% |
| BPMC | New | BLUEPRINT MEDICINES CORP | $8,796,000 | – | 100,000 | +100.0% | 0.18% | – |
| RXRX | New | RECURSION PHARMACEUTICALS INcl a | $7,300,000 | – | 200,000 | +100.0% | 0.15% | – |
| ORIC | Buy | ORIC PHARMACEUTICALS INC | $7,076,000 | +188.8% | 400,000 | +300.0% | 0.14% | +234.9% |
| FUSN | Buy | FUSION PHARMACEUTICALS INC | $6,060,000 | +4.8% | 750,000 | +39.1% | 0.12% | +20.6% |
| BHG | New | BRIGHT HEALTH GROUP INC | $5,243,000 | – | 305,555 | +100.0% | 0.11% | – |
| DYNS | New | DYNAMICS SPECIAL PURPOSE COR | $4,970,000 | – | 500,000 | +100.0% | 0.10% | – |
| ALDX | New | ALDEYRA THERAPEUTICS INC | $4,893,000 | – | 431,894 | +100.0% | 0.10% | – |
| IMMP | New | IMMUTEP LTDsponsored ads | $3,870,000 | – | 1,000,000 | +100.0% | 0.08% | – |
| VIAC | Buy | VIACOMCBS INCcl b | $3,390,000 | +11.4% | 75,000 | +11.1% | 0.07% | +27.8% |
| MEIP | Buy | MEI PHARMA INC | $2,850,000 | +9.3% | 1,000,000 | +31.6% | 0.06% | +26.1% |
| MOLN | New | MOLECULAR PARTNERS AGads | $2,049,000 | – | 100,000 | +100.0% | 0.04% | – |
| LU | New | LUFAX HOLDING LTD | $565,000 | – | 50,000 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGENUS INC | 42 | Q3 2023 | 1.9% |
| IRONWOOD PHARMACEUTICALS INC | 42 | Q3 2023 | 0.3% |
| ALNYLAM PHARMACEUTICALS INC | 37 | Q3 2023 | 5.1% |
| LEXICON PHARMACEUTICALS INC | 34 | Q3 2023 | 20.6% |
| AMICUS THERAPEUTICS INC | 30 | Q3 2023 | 2.7% |
| BEIGENE LTD | 28 | Q3 2023 | 7.4% |
| BK OF AMERICA CORP | 28 | Q1 2021 | 4.3% |
| SAGE THERAPEUTICS INC | 28 | Q2 2023 | 1.9% |
| AGIOS PHARMACEUTICALS INC | 28 | Q2 2020 | 1.1% |
| NEKTAR THERAPEUTICS | 27 | Q2 2020 | 1.3% |
View Artal Group S.A.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| WEIGHT WATCHERS INTERNATIONAL INC | February 13, 2015 | 29,443,300 | 51.9% |
View Artal Group S.A.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-25 |
| 4 | 2024-03-13 |
| 4 | 2024-02-29 |
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-10-16 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-06-22 |
| 3 | 2023-06-15 |
| 4 | 2023-06-05 |
View Artal Group S.A.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.